AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. MBRX
  4. [Form 4] Moleculin Biotech, Inc. Insider Trading Activity

[Form 4] Moleculin Biotech, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Walter V. Klemp, CEO, President and Director of Moleculin Biotech (MBRX), reported multiple insider transactions on June 20-23, 2025:

  • Acquired 3,750 shares from RSU vesting on June 20, with 914 shares withheld for taxes
  • Acquired 8,990 shares from RSU vesting on June 22, with 2,190 shares withheld for taxes
  • Purchased 675,675 common shares at $0.37 per share in a public offering on June 23
  • Acquired Series E warrants to purchase 2,027,025 additional shares at $0.37/share

Following these transactions, Klemp directly owns 743,607 common shares and 2,409,481 derivative securities. The Series E warrants will be exercisable upon stockholder approval and expire 5 years after approval. These transactions demonstrate significant insider investment in the company, particularly through participation in the public offering.

Walter V. Klemp, CEO, Presidente e Direttore di Moleculin Biotech (MBRX), ha comunicato diverse operazioni interne tra il 20 e il 23 giugno 2025:

  • Ha acquisito 3.750 azioni derivanti dalla maturazione di RSU il 20 giugno, con 914 azioni trattenute per tasse
  • Ha acquisito 8.990 azioni derivanti dalla maturazione di RSU il 22 giugno, con 2.190 azioni trattenute per tasse
  • Ha acquistato 675.675 azioni ordinarie a 0,37$ per azione in un'offerta pubblica il 23 giugno
  • Ha acquisito warrant Serie E per acquistare ulteriori 2.027.025 azioni a 0,37$ ciascuna

Dopo queste operazioni, Klemp possiede direttamente 743.607 azioni ordinarie e 2.409.481 titoli derivati. I warrant Serie E saranno esercitabili previa approvazione degli azionisti e scadranno 5 anni dopo tale approvazione. Queste operazioni evidenziano un significativo investimento interno nella societ脿, soprattutto tramite la partecipazione all'offerta pubblica.

Walter V. Klemp, CEO, Presidente y Director de Moleculin Biotech (MBRX), inform贸 m煤ltiples transacciones internas entre el 20 y el 23 de junio de 2025:

  • Adquiri贸 3,750 acciones por la consolidaci贸n de RSU el 20 de junio, reteniendo 914 acciones para impuestos
  • Adquiri贸 8,990 acciones por la consolidaci贸n de RSU el 22 de junio, reteniendo 2,190 acciones para impuestos
  • Compr贸 675,675 acciones comunes a $0.37 por acci贸n en una oferta p煤blica el 23 de junio
  • Adquiri贸 warrants Serie E para comprar 2,027,025 acciones adicionales a $0.37 cada una

Tras estas transacciones, Klemp posee directamente 743,607 acciones comunes y 2,409,481 valores derivados. Los warrants Serie E ser谩n ejercibles tras la aprobaci贸n de los accionistas y expirar谩n 5 a帽os despu茅s de dicha aprobaci贸n. Estas operaciones reflejan una inversi贸n interna significativa en la compa帽铆a, especialmente mediante la participaci贸n en la oferta p煤blica.

Walter V. Klemp, Moleculin Biotech (MBRX)鞚� CEO, 靷灔 氚� 鞚挫偓搿滌劀 2025雲� 6鞗� 20鞚茧秬韯� 23鞚缄箤歆� 鞐煬 雮措秬 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟:

  • 6鞗� 20鞚� RSU 氩犾姢韺呾溂搿� 3,750欤� 旆摑, 靹戈笀鞙茧 914欤� 鞗愳矞歆曥垬
  • 6鞗� 22鞚� RSU 氩犾姢韺呾溂搿� 8,990欤� 旆摑, 靹戈笀鞙茧 2,190欤� 鞗愳矞歆曥垬
  • 6鞗� 23鞚� 瓿惦鞐愳劀 欤茧嫻 $0.37鞐� 氤错喌欤� 675,675欤� 毵れ瀰
  • 欤茧嫻 $0.37鞐� 於旉皜 2,027,025欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 鞁滊Μ歃� E 鞗岆煱韸� 旆摑

鞚� 瓯半灅霌� 鞚错泟 Klemp電� 歆侅爲 氤错喌欤� 743,607欤检檧 韺岇儩歃濌秾 2,409,481欤茧ゼ 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�. 鞁滊Μ歃� E 鞗岆煱韸鸽姅 欤检＜ 鞀轨澑 頉� 頄夓偓 臧�電ロ晿氅� 鞀轨澑鞚茧攵�韯� 5雲� 頉� 毵岆霅╇媹雼�. 鞚� 瓯半灅霌れ潃 韸鬼瀳 瓿惦 彀胳棳毳� 韱淀暣 須岇偓鞐� 雽�頃� 欷戩殧頃� 雮措秬 韴瀽鞛勳潉 氤挫棳欷嶋媹雼�.

Walter V. Klemp, PDG, Pr茅sident et Directeur de Moleculin Biotech (MBRX), a d茅clar茅 plusieurs transactions d'initi茅s du 20 au 23 juin 2025 :

  • A acquis 3 750 actions issues de la lev茅e des RSU le 20 juin, avec 914 actions retenues pour imp么ts
  • A acquis 8 990 actions issues de la lev茅e des RSU le 22 juin, avec 2 190 actions retenues pour imp么ts
  • A achet茅 675 675 actions ordinaires 脿 0,37 $ par action lors d'une offre publique le 23 juin
  • A acquis des bons de souscription S茅rie E pour acheter 2 027 025 actions suppl茅mentaires 脿 0,37 $ chacune

Apr猫s ces transactions, Klemp d茅tient directement 743 607 actions ordinaires et 2 409 481 titres d茅riv茅s. Les bons de souscription S茅rie E seront exer莽ables apr猫s approbation des actionnaires et expireront 5 ans apr猫s cette approbation. Ces transactions d茅montrent un investissement interne important dans la soci茅t茅, notamment par la participation 脿 l'offre publique.

Walter V. Klemp, CEO, Pr盲sident und Direktor von Moleculin Biotech (MBRX), meldete mehrere Insider-Transaktionen vom 20. bis 23. Juni 2025:

  • Erwarb am 20. Juni 3.750 Aktien durch RSU-Vesting, wobei 914 Aktien f眉r Steuern einbehalten wurden
  • Erwarb am 22. Juni 8.990 Aktien durch RSU-Vesting, wobei 2.190 Aktien f眉r Steuern einbehalten wurden
  • Erwarb am 23. Juni 675.675 Stammaktien zu je 0,37 $ in einem 枚ffentlichen Angebot
  • Erhielt Series E Warrants zum Kauf von zus盲tzlich 2.027.025 Aktien zu je 0,37 $

Nach diesen Transaktionen besitzt Klemp direkt 743.607 Stammaktien und 2.409.481 derivative Wertpapiere. Die Series E Warrants werden mit Zustimmung der Aktion盲re aus眉bbar sein und verfallen 5 Jahre nach der Zustimmung. Diese Transaktionen zeigen eine bedeutende Insider-Investition in das Unternehmen, insbesondere durch die Teilnahme am 枚ffentlichen Angebot.

Positive
  • CEO Walter Klemp made a significant open market purchase of 675,675 shares at $0.37 per share, representing a substantial personal investment of approximately $250,000
  • CEO acquired Series E warrants to purchase an additional 2,027,025 shares at $0.37, demonstrating strong long-term confidence in the company
Negative
  • None.

Walter V. Klemp, CEO, Presidente e Direttore di Moleculin Biotech (MBRX), ha comunicato diverse operazioni interne tra il 20 e il 23 giugno 2025:

  • Ha acquisito 3.750 azioni derivanti dalla maturazione di RSU il 20 giugno, con 914 azioni trattenute per tasse
  • Ha acquisito 8.990 azioni derivanti dalla maturazione di RSU il 22 giugno, con 2.190 azioni trattenute per tasse
  • Ha acquistato 675.675 azioni ordinarie a 0,37$ per azione in un'offerta pubblica il 23 giugno
  • Ha acquisito warrant Serie E per acquistare ulteriori 2.027.025 azioni a 0,37$ ciascuna

Dopo queste operazioni, Klemp possiede direttamente 743.607 azioni ordinarie e 2.409.481 titoli derivati. I warrant Serie E saranno esercitabili previa approvazione degli azionisti e scadranno 5 anni dopo tale approvazione. Queste operazioni evidenziano un significativo investimento interno nella societ脿, soprattutto tramite la partecipazione all'offerta pubblica.

Walter V. Klemp, CEO, Presidente y Director de Moleculin Biotech (MBRX), inform贸 m煤ltiples transacciones internas entre el 20 y el 23 de junio de 2025:

  • Adquiri贸 3,750 acciones por la consolidaci贸n de RSU el 20 de junio, reteniendo 914 acciones para impuestos
  • Adquiri贸 8,990 acciones por la consolidaci贸n de RSU el 22 de junio, reteniendo 2,190 acciones para impuestos
  • Compr贸 675,675 acciones comunes a $0.37 por acci贸n en una oferta p煤blica el 23 de junio
  • Adquiri贸 warrants Serie E para comprar 2,027,025 acciones adicionales a $0.37 cada una

Tras estas transacciones, Klemp posee directamente 743,607 acciones comunes y 2,409,481 valores derivados. Los warrants Serie E ser谩n ejercibles tras la aprobaci贸n de los accionistas y expirar谩n 5 a帽os despu茅s de dicha aprobaci贸n. Estas operaciones reflejan una inversi贸n interna significativa en la compa帽铆a, especialmente mediante la participaci贸n en la oferta p煤blica.

Walter V. Klemp, Moleculin Biotech (MBRX)鞚� CEO, 靷灔 氚� 鞚挫偓搿滌劀 2025雲� 6鞗� 20鞚茧秬韯� 23鞚缄箤歆� 鞐煬 雮措秬 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟:

  • 6鞗� 20鞚� RSU 氩犾姢韺呾溂搿� 3,750欤� 旆摑, 靹戈笀鞙茧 914欤� 鞗愳矞歆曥垬
  • 6鞗� 22鞚� RSU 氩犾姢韺呾溂搿� 8,990欤� 旆摑, 靹戈笀鞙茧 2,190欤� 鞗愳矞歆曥垬
  • 6鞗� 23鞚� 瓿惦鞐愳劀 欤茧嫻 $0.37鞐� 氤错喌欤� 675,675欤� 毵れ瀰
  • 欤茧嫻 $0.37鞐� 於旉皜 2,027,025欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 鞁滊Μ歃� E 鞗岆煱韸� 旆摑

鞚� 瓯半灅霌� 鞚错泟 Klemp電� 歆侅爲 氤错喌欤� 743,607欤检檧 韺岇儩歃濌秾 2,409,481欤茧ゼ 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�. 鞁滊Μ歃� E 鞗岆煱韸鸽姅 欤检＜ 鞀轨澑 頉� 頄夓偓 臧�電ロ晿氅� 鞀轨澑鞚茧攵�韯� 5雲� 頉� 毵岆霅╇媹雼�. 鞚� 瓯半灅霌れ潃 韸鬼瀳 瓿惦 彀胳棳毳� 韱淀暣 須岇偓鞐� 雽�頃� 欷戩殧頃� 雮措秬 韴瀽鞛勳潉 氤挫棳欷嶋媹雼�.

Walter V. Klemp, PDG, Pr茅sident et Directeur de Moleculin Biotech (MBRX), a d茅clar茅 plusieurs transactions d'initi茅s du 20 au 23 juin 2025 :

  • A acquis 3 750 actions issues de la lev茅e des RSU le 20 juin, avec 914 actions retenues pour imp么ts
  • A acquis 8 990 actions issues de la lev茅e des RSU le 22 juin, avec 2 190 actions retenues pour imp么ts
  • A achet茅 675 675 actions ordinaires 脿 0,37 $ par action lors d'une offre publique le 23 juin
  • A acquis des bons de souscription S茅rie E pour acheter 2 027 025 actions suppl茅mentaires 脿 0,37 $ chacune

Apr猫s ces transactions, Klemp d茅tient directement 743 607 actions ordinaires et 2 409 481 titres d茅riv茅s. Les bons de souscription S茅rie E seront exer莽ables apr猫s approbation des actionnaires et expireront 5 ans apr猫s cette approbation. Ces transactions d茅montrent un investissement interne important dans la soci茅t茅, notamment par la participation 脿 l'offre publique.

Walter V. Klemp, CEO, Pr盲sident und Direktor von Moleculin Biotech (MBRX), meldete mehrere Insider-Transaktionen vom 20. bis 23. Juni 2025:

  • Erwarb am 20. Juni 3.750 Aktien durch RSU-Vesting, wobei 914 Aktien f眉r Steuern einbehalten wurden
  • Erwarb am 22. Juni 8.990 Aktien durch RSU-Vesting, wobei 2.190 Aktien f眉r Steuern einbehalten wurden
  • Erwarb am 23. Juni 675.675 Stammaktien zu je 0,37 $ in einem 枚ffentlichen Angebot
  • Erhielt Series E Warrants zum Kauf von zus盲tzlich 2.027.025 Aktien zu je 0,37 $

Nach diesen Transaktionen besitzt Klemp direkt 743.607 Stammaktien und 2.409.481 derivative Wertpapiere. Die Series E Warrants werden mit Zustimmung der Aktion盲re aus眉bbar sein und verfallen 5 Jahre nach der Zustimmung. Diese Transaktionen zeigen eine bedeutende Insider-Investition in das Unternehmen, insbesondere durch die Teilnahme am 枚ffentlichen Angebot.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
KLEMP WALTER V
(Last) (First) (Middle)
C/O MOLECULIN BIOTECH, INC.
5300 MEMORIAL DR., SUITE 950
(Street)
HOUSTON TX 77007
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Moleculin Biotech, Inc. [ MBRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CEO and President
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 M 3,750 A (1) 62,046 D
Common Stock 06/20/2025 F 914(2) D $0.267 61,132 D
Common Stock 06/22/2025 M 8,990 A (1) 70,122 D
Common Stock 06/22/2025 F 2,190(2) D $0.267 67,932 D
Common Stock 06/23/2025 P 675,675 A $0.37(5) 743,607 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 06/20/2025 M 3,750 (3) (3) Common Stock 3,750 $0 391,446 D
Restricted Stock Units (1) 06/22/2025 M 8,990 (4) (4) Common Stock 8,990 $0 382,456 D
Series E Warrants $0.37 06/23/2025 P 2,027,025 (5) (5) Common Stock 2,027,025 (5) 2,409,481 D
Explanation of Responses:
1. Restricted stock units convert into common stock on a one-for-one basis.
2. Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
3. On June 20, 2022, the reporting person was granted 15,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
4. On June 22, 2023, the reporting person was granted 35,959 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
5. On June 23, 2025, the reporting person acquired 675,675 shares of common stock and Series E warrants to purchase 2,027,025 shares of common stock at a purchase price of $0.37 per share and accompanying warrants in a public offering. The Series E warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series E warrants and will expire five years from the date of such approval.
/s/ Jonathan P. Foster by Power of Attorney 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many MBRX shares did CEO Walter Klemp purchase in the June 2025 public offering?

CEO Walter Klemp purchased 675,675 shares of MBRX common stock at $0.37 per share in a public offering on June 23, 2025. Along with the shares, he also received Series E warrants to purchase an additional 2,027,025 shares.

What is the exercise price of MBRX's Series E warrants issued in June 2025?

The Series E warrants have an exercise price of $0.37 per share. These warrants will be exercisable after stockholder approval and will expire five years from the approval date.

How many restricted stock units (RSUs) vested for MBRX's CEO in June 2025?

In June 2025, a total of 12,740 restricted stock units (RSUs) vested for CEO Walter Klemp, consisting of 3,750 RSUs that vested on June 20, 2025, and 8,990 RSUs that vested on June 22, 2025.

What is the total number of MBRX shares beneficially owned by Walter Klemp after the June 2025 transactions?

Following all reported transactions in June 2025, Walter Klemp directly owned 743,607 shares of MBRX common stock. Additionally, he held Series E warrants for 2,027,025 shares and 382,456 unvested restricted stock units.

How many MBRX shares were withheld for tax purposes from CEO Klemp's RSU vestings?

A total of 3,104 shares were withheld for tax purposes, consisting of 914 shares withheld on June 20, 2025, and 2,190 shares withheld on June 22, 2025, at a price of $0.267 per share.
Stock MBRX logo
Moleculin Biotec

NASDAQ:MBRX

MBRX Rankings

#9135 Ranked by Market Cap
N/A Ranked by Dividends
#129 Top Loser

MBRX Latest News

Jul 9, 2025
Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans
Jun 20, 2025
Moleculin Announces $5.9 Million Public Offering
Jun 18, 2025
Moleculin Participates in Virtual Investor 鈥淲hat This Means鈥� Segment
Jun 18, 2025
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML
Jun 11, 2025
Moleculin Participates in Virtual Investor 鈥淲hat This Means鈥� Segment

MBRX Latest SEC Filings

Jul 9, 2025
[8-K] Moleculin Biotech, Inc. Reports Material Event
Jul 8, 2025
[DEFA14A] Moleculin Biotech, Inc. Additional Proxy Soliciting Materials
Jul 8, 2025
[DEF 14A] Moleculin Biotech, Inc. Definitive Proxy Statement
Jun 23, 2025
[8-K] Moleculin Biotech, Inc. Reports Material Event
Jun 23, 2025
[Form 4] Moleculin Biotech, Inc. Insider Trading Activity

MBRX Stock Data

4.58M
23.03M
0.75%
3.49%
9.01%
Biotechnology
Pharmaceutical Preparations
United States
HOUSTON